Sublingual desensitization in patients with wasp venom allergy: Preliminary results

International Journal of Immunopathology and Pharmacology

Volumn 21, Issue 3, 2008, Pages 669-677

  Patriarca, Giampiero ^a   Nucera, E ^a   Roncallo, C ^a   Aruanno, A ^a   Lombardo, C ^a   Decinti, M ^a   Pascolini, L ^a   Milani, M ^b   Buonomo, A ^a   Schiavino, D ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b ALK Abello Group   (Italy)

Author keywords

Case control trial; Sublingual specific immunotherapy; Wasp venom allergy

Indexed keywords

ANTIHISTAMINIC AGENT; AQUAGEN; BETAMETHASONE; CORTICOSTEROID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; PHARMALGEN; UNCLASSIFIED DRUG; VESPULA VENOM;

ADULT; AGED; ANAMNESIS; ANTIBODY SPECIFICITY; ARTICLE; BEE STING; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DESENSITIZATION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INSECT ALLERGY; MAINTENANCE DRUG DOSE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PRURITUS; SKIN TEST; STOMACH PAIN;

EID: 53749106158     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200802100321     Document Type: Article

References (41)

1. Müller U, Mosbech H. Immunotherapy with Hymenopetra venoms. Allergy 1993; 48:36-46.
2. Charpin D, Birnbaum J, Vervloet D. Epidemiology of hymenptera allergy. Clin Exp Allergy 1994; 24:1010-5.
3. Kalyoncu AF, Demir AU, Ozcan U et al. Bee and wasp venom allergy in Turkey. Aann Allergy Asthma Immunol 1997; 78:408-12.
4. Golden DBK. Insect sting allergy and venom immunotherapy: A model and a mystery. J Allergy Clin Immunol 2005; 115:439-47.
5. Schwartz HJ, Sutheimer C, Gauerke B et al. Venom-specific IgE antibodies in postmortem sera from victims of sudden unexplained death. J Allergy Clin Immunol 984; 73:189-93.
6. Hoffman DR. Fatal reactions to Hymenoptera stings. Asthma Allergy Proc 2003; 24:1-5.
7. Biló MB, Rueff F, Mosbech H et al. Diagnosis of Hymenoptera venom allergy. Allergy 2005; 60:1339-49.
8. Müller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966; 3:331-33.
9. Gillman SA, Cummins LH, Kozak PP et al. Venom immunotherapy: comparison of "rush" vs "conventional" schedules. Ann Allergy 1980; 45: 351-4.
10. Laurent J, Smiejan JM, Bloch-Morot E et al. Safety of Hymenoptera venom rush immunotherapy. Allergy 1997; 52:94-96.
11. Schiavino D, Nucera E, Pollastrini E et al. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol 2004; 92:409-13.
12. Roll A, Hofbauer G, Ballmer-Weber BK et al. Safety of specific immunotherapy using a four-hour ultrarush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol 2006; 16:79-85.
13. Bonifazi F, Jutel M, Bilò BM et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-70.
14. Mosbech E, Müller U. Side-effects of insect venom immunotherapy: results from a EAACI multicenter study. Allergy 2000; 55:1005-10.
15. Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993; 23: 226-30.
16. La Rosa M, Ranno C, André C et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104:425-32.
17. Canonica GW, Passalacqua G. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients. Allergy 2006; 61(S):20-3.
18. Penagos M, Compalati E, Tarantini F et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomised, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006; 97:141-8.
19. Calamita Z, Saconato H, Pelá AB et al. Efficacy of sublingual immunotherapy in asthma: systemic review of randomised-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61: 1162-72.
20. Ozdemir C, Yazi D, Goemen I et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust-mite allergic children with asthma. Pediatr Allergy Immunol 2007; 18:508-15.
21. Tripodi S, Di Rienzo Businco A, Benincori N et al. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol 2006; 139:149-52.
22. Vervlo et D, Birnbaum J, Laurent P et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Int Arch Allergy Immunol 2007; 142:239-46.
23. Bohle B, Kinaciyan T, Gerstmayr M et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-13.
24. Severino MG, Cortellini G, Bonadonna P, Francescato E, Panzini I, Macchia D, Campi P, Spadolini I, Canonica WG, Passalacqua G. Sublingual immunotherapy for large local reactions caused by honeybee sting: A double-blind, placebo-controlled trial. J Allergy Clin Immunol 2008; 122: 44-8.
25. Lichtenstein LM, Valentine MD, Sobotka AK. A case for venom treatment in anaphylactic sensitivity to Hymenoptera. sting. N Engl J Med 1974; 290:1223-7.
26. Hoffman DR, Jacobson RS. Allergens in Hymenoptera venoms. XII. How much protein is in a sting? Ann Allergy 1984; 52:276-8.
27. Pasaoglu G, Sin BA, Misirligil Z. Rush hymenoptera venom immunotherapy is efficacious and safe. J Investig Allergol Clin Immunol 2006; 16:232-8.
28. Brehler R, Wolf H, Kutting B et al. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000; 105:1231-5.
29. Wilson DR, Torres L, Durham SR. Sublingual immunotherapy for allergic rhinitis. Allergy 2005; 60:3-8.
30. Lang R, Hawranek T. Hymenoptera venom immunotherapy and field stings. J Investig Allergol Clin Immunol 2006; 16:224-31.
31. Aberer W, Hawranek T, Reider N et al. Immunoglobulin E and G antibody profiles to grass pollen allergens during a short course of sublingual immunotherapy. J Investig Allergol Clin Immunol 2007; 17:131-6.
32. Rolinck-Werninghaus C, Kopp M, Liebke C et al. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005; 136:134-41.
33. Bahceciler NN, Arikan C, Taylor A et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136:287-94.
34. Patriarca G, Nucera E, Pollastrini E et al. Sublingual desensitization: a new approach to latex allergy problem. Anesth Analg 2002; 95:956-60.
35. Dehlink E, Eiwegger T, Gerstmayr M et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006; 36:32-9.
36. de Blay F, Barnig C, Kanny G et al. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2007; 99:453-61.
37. Bufe A, Ziegler-Kirbach E, Stoeckmann E et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004; 59:498-504.
38. Lue KE, Lin YH, Sun HL et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitised to mites: a double-blind, randomised, placebo-controlled study. Pediatr Allergy Immunol 2006; 17:408-15.
39. Vervloet D, Birnbaum J, Laurent P et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Int Arch Allergy Immunol 2007; 142:239-46.
40. Moingeon P, Batard T, Fadel R et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:151-65.
41. Ciprandi G, Fenoglio D, Cirillo I et al. Sublingual HDM-specific immunotherapy induces IL-10 production: preliminary report. Ann Astham Allergy Immunol 2005; 95:38-44.